The state of Michigan currently has 27 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™). evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/20/2024
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +1 locations
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
03/20/2024
Locations: University of Michigan Medical Center, Ann Arbor, Michigan +4 locations
Conditions: Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/20/2024
Locations: Henry Ford Health System, Detroit, Michigan +1 locations
Conditions: Atopic Dermatitis
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Recruiting
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 3-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, SAR444656 dose 2 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Revival Research Corporation Site Number: 8400007, Troy, Michigan
Conditions: Atopic Dermatitis
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
Recruiting
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses. The trial will last up to 36 weeks... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/14/2024
Locations: LEO Investigational Site, Ann Arbor, Michigan
Conditions: Atopic Dermatitis
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening and then up to approximately day 378 (last dose on day 280 + 98 days safety follow-up) for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/11/2024
Locations: Revival Research Corporation, Troy, Michigan
Conditions: Moderate to Severe Atopic Dermatitis
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
Recruiting
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Inno-6050 Site 17, Auburn Hills, Michigan
Conditions: Atopic Dermatitis
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
Recruiting
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various time... Read More
Gender:
All
Ages:
Between 10 years and 55 years
Trial Updated:
03/07/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis, Food Allergy, Healthy
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Recruiting
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Wayne State University Physician Group Dermatology, Dearborn, Michigan +1 locations
Conditions: Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
02/29/2024
Locations: Revival Research Institute - Troy, Troy, Michigan
Conditions: Atopic Dermatitis
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Recruiting
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Oakland Hills Dermatology, Auburn Hills, Michigan +1 locations
Conditions: Atopic Dermatitis
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
02/28/2024
Locations: Oakland Hills Dermatology, Auburn Hills, Michigan +2 locations
Conditions: Atopic Dermatitis, Eczema